PSMD1 and 22q11.2 deletion syndrome: Pulvirenti et al. reported that among CVID patients, the percentage of patients with measurable anti-S1 IgG dose rose from 20 % to 64 % after the 3rd dose, they also in another study among 16 patients with 22q11.2 deletion syndrome found that anti-S1 antibody titers decreased over time while they were significantly boosted by the 3rd dose (Pulvirenti et al., 2022, Pulvirenti et al., 2023).